John Libbey Eurotext

Hématologie

Quel recul sur la sécurité du romiplostim dans les syndromes myélodysplasiques ? Volume 23, numéro 4, Juillet-Août 2017

  • [1] Greenberg P., Cox C., LeBeau M.M. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
  • [2] Kantarjian H., O’Brien S., Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351-1361.
  • [3] Kantarjian H., Giles F., List A. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705-1714.
  • [4] Kuter D.J., Bussel J.B., Lyons R.M. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395-403.
  • [5] Kuter D.J., Rummel M., Boccia R. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889-1899.
  • [6] Giagounidis A., Mufti G.J., Fenaux P. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120:1838-1846.
  • [7] Sekeres M.A., Kantarjian H., Fenaux P. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer. 2011;11:992-1000.
  • [8] Kantarjian H., Fenaux P., Sekeres M.A. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28:437-444.
  • [9] Nplate (romiplostim) : Risque de progression de la maladie vers une leucémie aiguë myéloïde au cours du traitement chez les patients présentant un syndrome myélodysplasique - Lettre aux professionnels de santé - ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 3 juill 2017]. Disponible sur: http://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Nplate-romiplostim-Risque-de-progression-de-la-maladie-vers-une-leucemie-aiguee-myeloide-au-cours-du-traitement-chez-les-patients-presentant-un-syndrome-myelodysplasique-Lettre-aux-professionnels-de-sante.
  • [10] Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol 14 juin 2017; DOI 1111/BJH14788.
  • [11] Wendling F., Penciolelli J.F., Charon M., Tambourin P. Factor-independent erythropoietic progenitor cells in leukemia induced by the myeloproliferative leukemia virus. Blood. 1989;73:1161-1167.
  • [12] NCCN Clinical Practice Guidelines in Oncology [Internet]. [cité 3 juill 2017]. Disponible sur : https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
  • [13] Oliva E.N., Alati C., Santini V. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127-e136.